Tom MacDonald is Professor of Clinical Pharmacology & Pharmacoepidemiology at the University of Dundee and Honorary Consultant Physician at Ninewells Hospital & Medical School, Dundee, Scotland, UK. He is also the Director of MEMO Research and the Hypertension Research Centre (HRC) within the Medical School at the University. He is the Co-Chair of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Currently, he is the principal investigator of a large, multi-national, multi-centre streamlined safety study, Febuxostat versus Allopurinol Safety Trial (FAST). He is also the PI for the Treatment In the Morning versus Evening (TIME) study which has randomised >21,000 patients. He is active in a number of learned societies and is a past president of both the International Society of Pharmacoepidemiology (ISPE) and the British & Irish Hypertension Society (BIHS). He has published extensively on hypertension, cardiovascular disorders and safety of medicines, especially the safety of non-steroidal anti-inflammatory drugs (NSAIDs).